is the CFO looking to exit?
Good set of results from the company, they have maintained 60 cr.+ quarterly revenue runrate and are confident of growing topline by 20%+ in FY22. After that, they are aspiring for 15-20% revenue growth. Here are my notes from the concall.
- Strengthened market share in building material segment and got new customers in dairy foods division
- Got FDA approval for masks division; Currently this division is doing 2-2.5 cr. monthly revenues. Will look at supplying to US customers. Don’t have clear visibility on growth as it is very covid wave specific. Don’t need any further capex for ramping up mask division
- Sold ~2100 printers in 9MFY22, looking to reach 3000 this years
- Have lower market share in packaging side compared to industrial side. Packaging is also bigger in terms of market size than industrial and has a more diverse mix of printers. Slowly gaining market share on packaging side because of new printers launched in the last 3 years which was not company’s specialization before
- On line for 20% sales growth in FY22, after that aspire to grow sales at 15-20%
- Guwahati consumable capacity utilization is 50-55%, capacity was built keep a long term demand in focus
Disclosure: Invested (position size here)
Have they set up a facility to manufacture masks?
And even if they didn’t, why are they putting in capital and resources into an unrelated commoditised business whose time is over?
While the other stuff sounds okay, such capital allocation decisions would only distract management from the core business where the need to beat strong, well-funded competitors.
Yes the capacity was already setup to manufacture masks at very minimal investment. In the beginning this was done as a CSR activity, however now they are doing 2-2.5 cr. monthly sales (meaning 25-30 cr. annual nos.). On a 230-240 cr. base, this is already quite significant. However, I will not hold my breath for growth from mask division, its directly a function of covid waves.
About capital allocation, management has been very quite prudent with capex returning a large part of free cash back to shareholders (~50% payout).
About mask being a commoditised business, I am not very sure. They are only the fourth Indian company to get FDA permission to sell masks in US. For context, we have 100+ Indian pharma companies selling drugs, I don’t know which one is more of a commodity.
Pharma products can be both commoditised or niche, not sure about the point of your argument. Some pharma companies have great ROIC while others struggle to even meet the cost of capital.
Masks are pretty much commoditised, with no niche really possible in most cases. Not much point in looking at only Indian suppliers since Chinese dominate.
Also, not sure why you’re looking at just revenues, when ultimately return on capital employed and growth matter.
Growth without value accretion to shareholders is worse than no growth, because management spends time and resources on a low potential business.
Like I said, I like the core business and the many seems capable, but this decision seems hasty. I have a feeling that the mask business won’t even be mentioned by next year.
Again, just an opinion.
Another good set of results from the company, quarterly sales has grown past 70 cr. and company has made inroads into competitor accounts in pharma division. My notes from concall are below.
- Consumable sales for the newer printers (TIJ/TTO) are lower (at 80’000 – 100’000 per printer) as customers are new to this printer and will ramp up gradually. Older (CIJ) printer consumable sales are higher at 1-1.2 lakh
- Sold 3025 printers in FY22, installed base (i.e. active ones) have crossed 15’000
- In this quarter, printer sales ~ 18-19%, consumable ~ 51-52%, services ~ 21-22%
- Not concentrating on mask division as of now, the related assets should be depreciated by end of FY23
- Have a backlog of CIJ printer orders due to chip shortage (could have sold 75-100 printers more if not for the chip shortage)
- Current inventory situation is at normalized level (65-70 cr.)
- Won competitor account in pharma segment
- Do not undercut competitors on price, compete on services
- Utilization in consumable segment is 50-55%
Disclosure: Invested (position size here, sold few shares in last-30 days)
Domestic market share: 18.5% market share
Business strategic focus:
- Dedicated managers in sectors (Dairy, Beverages, Bakery (Biscuits), Frozen Food, Ready to Eat, Pharma, Packaging, Plywood, Lubricants, Carton Coding)
- Increased conversion strike rate by growing sales staff for tele communicating with customers
- Continuous inkjet (largest market share due to high speed + efficiency on any surface + low cost continuous printing)
- Drop-on-demand (DoD)
- Ribbon-based technology
- CO2 technology
- Hot roll coders
- Laser coding and marking
- Thermal inkjet (TIJ)
- Thermal transfer overprinting (TTO)
- Developed 230 ml. Maxi Cartridge. This is Unique Model with 4x ink capacity and company has applied for IP Rights
- Implemented CRM software to centralize, optimize and streamline engagement with customers
- Small Character Printer (SCP): Growth was attributable to better output in sectors like dairy, healthcare, food, cable and wire, agrochemicals, pharma, paint and wood
- Laser: Gradually expanding with improvement of product technology and a new team
- Large Character Printer (LCP): Grew with modest improvement in cement & sugar sectors. With introduction of new applications, company is shifting attention to non- Cement industry
- Original Equipment Manufacturer (OEM): Approach for a separate vertical for major accounts and a more focused strategy is yielding promising results
- Impressive growth rates were registered by Thermal Inkjet Printer (TIJ), High Resolution Printer (HiRes) and the thermal transfer overprinter (TTO) divisions
- Aspire to grow revenues to 400 cr. in 3 years, should grow sales in double digits in FY23 while maintaining 24%+ EBITDA margins
- The newer products allow to print on any surface ensuring continuous operation
- Invested in Innovative Codes (Chennai based) to augment offerings in price sensitive segments. Revenues: 2.18 cr., PAT: (-0.66 cr.)
- Industry is witnessing shift towards coding and marking solutions which enables high-volume printing at high speeds (like continuous inkjet)
- 300+ sales and service field workers spread throughout 9 branch offices in India and Sri Lanka
- Strengthening in-house software development team to create comprehensive solutions to meet the customer needs
- In building materials section, Company increased market share. In dairy and food sectors, Company saw increased customer engagement
- Control Prints became the fourth Indian company to receive US FDA approval for surgical facemasks
- In view of economic and political uncertainty in Sri Lanka, company has decided to wind-up the Sri Lanka operation
- Export: Sri lanka, Bangladesh, Nepal, Bhutan, Kenya, Italy, Tanzania, Germany. Company has exported components used in Printer Manufacturing to its Technology Partners KBA-Metronic in Germany. Company has also started exporting components to KBA Metronic Plant in China
- 62 contractual employees (vs 48 in FY21)
- Contributed 1.18 cr. towards CSR (0.75 cr. in excess of required)
Disclosure: Invested (position size here, no transactions in last-30 days)
New to the company. Just wanted to know on how do you all feel the longevity of the business in terms of growth. And is the management walking the talk? coz I saw they mentioned to achieve 400cr of revenues but they did ~250-300 I guess…
(I might be completely wrong as well. just want to see other perspective.)
Control Print reported highest ever quarterly sales in last quater with 50%+ contribution from consumables (high gross margins); reported improvement in working capital cycle; future growth drivers is increased inroads into packing industry; capacity utilization is about 50%; I believe it is reasonably valued at PE of 20. Disclosure Invested.
Its a very sticky business with limited profit pool (therefore limited competition), and is a very good proxy to industrial growth. The delta in terms of growth in this sector is low as most printing is because of regulatory requirements and each competitor is quite good. This means that once a factory installs a printer on a production line, it will not change the supplier unless something goes very wrong. So, gaining competitor accounts is not easy and you need to have newer lines to penetrate into the customer.
About guidance, management didn’t guide 400 cr. in FY22 but by FY25. Growth wise, they have executed very well gaining accounts in newer sectors where they were not present before. Also, they are doing these small acquisitions (like Innovative Codes last year, Markprint recently) to increase potential market size. Additionally, company is investing in software vertical as they want to be a complete service provider (e.g. in pharma division, they have come up with QR code that tracks production batches which is implemently directly by Control Print instead of the pharma company). So, I feel management is trying very hard to unlock new growth avenues.
If you have any specific question, please feel free to ask. Hope this helps
Disclosure: Invested (position size here, no transactions in last-30 days)
Good set of results with 20%+ sales growth and higher EBITDA margins due to higher consumable sales. My notes from concall is below.
- Revenues were impacted due to supply chain problems (especially for semiconductors). Have been buying from spot market which increases costs by 40’000 per printer. Printers are generally sold at cost price, currently there is slight loss on sale of printers
- Good traction in consumables as industrial activity improved, still don’t believe production is at optimal level (can generate 10-15% higher consumable sales)
- Gross margin improvement was due to higher consumable sales
- Most growth in last year was volume driven, pricing was only 5-6%
- Focusing more on tele calling to increase lead conversion
- Import constituent account for 25-30% of raw material
- Printer: 18-19%, Consumables: 56-57%, Services: 22-23%, remainder mask division
- Sold 750 printers this quarter (CIJ is generally at 65-70% of total printer sales) – installed base is >15’500
- Markprint acquisition is to provide capability for higher end printers in order to meet customer requirements. Markprint has a printer base of 300 (making 1.5 mn Euro revenues per year and expect it to double in 2-3 years). They are into higher end printers. This will be the framework going forward, focus on acquiring capabilities
- In China, 30’000 TIJ printers are sold annually vs India sales of 14’000-15’000. In addition, there are other kind of printers sold in China
- Cement business declined a lot as customers didn’t care for quality of prints. This division had 3 lakh consumable sales per printer. As a result, consumable sales per printer has come down over time
- Current sales mix is more towards the industrial side (~60%) vs packaging (~40%). This should come down to 55% for industrial side and 45% for packaging over time
- Track& trace segment: currently revenues are negligible from this segment. Offering more customized capabilities to track each shipment and transitioning towards higher revenues from services
- Field staff count was mentioned as 300+ vs 360 earlier. There is actually no reduction in field staff, company is actually looking at increasing field staff due to higher business expectations
- Current capacity can cater to 300-350 cr. of sales, will require more warehousing space in Guwahati once they cross that
- Capital allocation: Will keep 50 cr. in terms of liquidity + 50 cr. in terms of bank limit. Remainder will be given back to shareholders
Disclosure: Invested (position size here, no transactions in last-30 days)
Control Print Q1 FY23 Result Update!!!
Recent Acquisition of Mark Print B.V. in Netherlands proves to be a good strategic decision to increase revenue streams.
Reasonable results, with 14% sales growth 16% EPS growth. They are facing a few supply chain problems resulting in subdued sales for new printers. However, consumable sales are growing very well. Concall notes below.
- Revenues were impacted due to supply chain problems where certain raw materials were purchased at higher prices to maintain sales. This has resulted in lower gross margins which will also be been in Q3 and continue till February or March
- Control’s competitors had supply change issues earlier when Control had enough inventory and as a result they were able to gain more business. Now, competitors seem to have rectified their supply chain problems, and Control is facing supply chain issues resulting in nonfulfillment to a few customers
- Consumable sales increased 29% YOY (vs 10% growth in revenues)
- To counter inflation, planning a price increase. They give 3-4 quarter notice to customers about price increase. Price increase should start contributing from Q4 and will fully reflect by August 2023
- Dairy segment grew by 20%+. Expect good growth from pipe and sugar sectors in Q3
- Launched a new TIJ printer called Pench
- Guwahati consumable capacity utilization is 40-50%, no need to spend capex to increase capacity
- Laser printer exports: Supplied to a large co-packers in consumer sector in Indonesia. This was the first orders which has established their base, and they feel going forward, it opens other regions for export of laser printer
- Sri Lanka resumption: Oligopoly market (4-player). Don’t want to leave that market, plan is to service existing customers. Converted pricing to USD based. Will not infuse fresh capital, will just service existing customers for the time being
- Mask contribution is ~3%
Disclosure: Invested (position size here, no transaction in last-30 days)
I had published a short post on this company on BLOG covering background, revenues, margins, capital needs, valuation, etc.
Since a lot of these points are already covered in this thread, I am sharing the valuation section, capital allocation issues and my personal thoughts sections of the above post here in the hope that it useful to members. In case it isn’t, feel free to report the same and get it deleted
PART I: DCF Valuation
- Lets assume that the company reaches its target of Rs 400 crores turnover by FY25 (on standalone basis). This implies a y-o-y growth of 16% from FY22. Lets also assume that it gets its desired EBIT margin of 21%. Lets also take the company’s words that they do not need any capex until this 400 crores turnover. What to do thereafter?
- I have put my positive thinking cap on and have taken these assumptions for more years. I have assumed that the company continues the aforesaid 16% growth for a total of 5 years (i.e. Until FY27), and thereafter it moderates to around 6% by year 10. This implies that by Year 10 the company will have a revenue of Rs 856 crores. Lets do a sanity check on this revenue projection. The current organized market is around Rs 1200 crores. If this market grows a CAGR of 12% y-o-y for 10 years it will be Rs 3727 crores by then. Thus, at Rs 856 crores, the company will have a marketshare of 23% (current marketshare around 18%). Hence this revenue projection, while optimistic, is not in the improbable territory.
- For the reinvestment needs I have not considered any capex until 400 crores and thereafter projected it at a FAT of 4.25. For the working capital I have assumed a turnover of 2.1 given the high working capital intensity of the business.
- For the terminal value I have retained the high margins of 21% as well as the above FAT & Working Capital turnover and thereby preserved a high ROIC of 22% and taken a perpetual growth rate of 6%.
- Thereafter, I have added back investments, cash book value of land of liberty chemical and other small items
- Lastly, I have used a discount rate of 13%
With these optimistic assumptions, the DCF yields a value of 455/share which is very close to the CMP (around 430). What this means is that we will earn a CAGR virtually equal to the discount rate of 13%. Now, you will note that this result is with fairly positive assumptions built-in
PART II: Multiple Based Valuation:
Lets assume that you do not believe in DCFs and consider them BS. From a multiple perspective, as per screener, the market is giving them a PE of 16 (TTM basis) as of now, which is around its average of 15. It would be fair to say that the market has already considered some growth prospects in this company. Now by FY25, if we expect sales to become Rs 400 crores and EBIT margins to be 20% with a tax rate of 18% (MAT rate applied due to hilly region benefit) we get Rs 65 crores of Profits in March-2025.
Now what multiple to apply for March-2025? If we take a multiple of 15 and divide by the share count we get a result of Rs 602/share i.e. a good CAGR of around 14.5%. However, we expecting things to be perfect. We expect that the company will deliver the promised growth & margins and are also expecting that the market will continue to give a multiple of 15. Do some sensitivity analysis on growth, margins and multiples and check whether if it fits your margin of safety & return expectations. If it does then you can invest at this price too
Some IMPORTANT things to be aware prior to investing in this company:
- Commission to directors: In addition to salary, the directors draw a commission. It was Rs 3.50 crores in FY22, Rs 2.60 in FY21 and Rs 1.70 crores in FY17. This could be ignored if it was in isolation. However, there other bigger things below
- Capital allocation history is not great
- Promoters also have a strong fancy to DIRECTLY invest in stocks. In FY22, this amount is Rs 39.31 crores which has increased from Rs 11.96 in FY17. Obviously some portion of this increase is attributable to the increase in value of the investment but still it is a large amount. Moreover such kind of equity investments are being done since the past decade! There is also an investment of Rs 0.5 crores in in Artha ‘Venture’ Fund along with a commitment of another Rs 0.5 crores (shown in contingent liability)
- Real Estate Diversification
As per FY11 AR, “Your Company has entered into a MOU with M/s. Liberty Chemicals Pvt. Ltd., in the month of August, 2008, towards purchase of its property and a sum of ` 1,35,00,000/- was paid as advance. Subsequently the Company has acquired all the shares of M/s. Liberty Chemicals Pvt. Ltd., in the month of April, 2011 after considering the assets and liabilities of Liberty Chemicals Pvt. Ltd”.
As per FY12 AR, the company invested another Rs 3.70 crore in the above subsidiary by way of rights issue. As stated in the AR “the acquisition would enhance shareholders value since Liberty Chemicals Private Limited owns a plot of land as a valuable asset. Control Print Limited intends to explore diversification in real estate business in future post feasibility study on its plans.” The aforementioned land located in Chandiwali, Mumbai is still with the company. While one cannot put a value to this real estate investment without further details, it is fairly safe to presume that the company will earn a profit (atleast on an absolute basis) on this investment since it was done way back in 2008. Will the profit exceed the time value of money on the investment made? When will the sale/development happen? Will the company distribute the proceeds to shareholders too? We cannot know as of now.
- The Promoters spent Rs 10 crores on the mask division in FY21 (as per Conf Call 26.4.21). However, as stated in various Conf Calls, this division is not central to their operations and they did it “basically in the pandemic period for the society and the CSR activity”.
All said and done the above shows the attitude of the promoter to invest company’s funds in different ventures. While the company has paid dividends, it is not to extent of the FCF generated by the company. However this attitude appears to be changing for the better. In the Conf Call 26.10.22, the company said:
“The board has decided that INR 50 crores is what we’ll keep as cash on books, including whatever investments, cash,bank balance, whatever form of liquid investment,how you’re going to term it, and we have our limits for any acquisition or other opportunities that come…….”
“And whatever more than INR50 crores the board has said that we will largely return back to the shareholder”
If you want to believe in what the management was stated, you can addback 50 crores to the assets. Consequently the Fixed Asset Turnover of the company will reduce and you can project the fixed assets requirements accordingly.
The company has a contingent liability payable to Videojet. Pursuant to an appeal made by the Company against an Arbitration Award, the Bombay HC Order had ordered an amount of Rs 2.30 crores to be deposited by the Company (Click here). The company has duly furnished a BG of that amount. I am no legal expert but upon reading the order a liability of Rs 2.30 crores looks likely. However BGs of this sort and that too to a High Court nowadays are not given by banks without corresponding cash/security collateral (sometimes to the tune of 100%) and hence this amount (in all likelihood and IMHO) may not have any impact from an ‘actual cash’ perspective since the company has already furnished the BG to the Court but will impact the P&L statement if & when the company loses the appeal.
P&L Statement shows inventory write-downs in several years (See: Exceptional items of these respective years). Rs 3.95 crores in FY21, Rs 6.12 crores in FY18, Rs 5.39 crores in FY17 and Rs 0.72 crores in FY15
Are these ‘exceptional’ items really ‘exceptional’? Need to do more digging in inventory (& also receivables) to get some context. I haven’t done it because the valuation (without considering the above) was already was too high for me
Some personal thoughts
I could have ignored most of the negative factors IF the stock price was lower. However, at the current price (around Rs 430/share), its a little difficult for me to ignore them as it cuts MY margin of safety. I believe that when a company does not share the proceeds with shareholders or is not a good capital allocator, our returns are more dependent on the moods of Mr. Market and/or the company meeting or exceeding the growth expectations especially since the margin of safety is not sufficient. Moreover, no investment can be seen in isolation and one must see what returns/risks their alternate investment options offer. Hence I have chosen to pass this one (for now).
On the other hand, lets not forget that the company is showing great sale of printers, has shown good growth in consumables, is showing better margins, is doing the right kind of acquisitions and has made a cap of Rs 50 crores on investments/cash. It could also enjoy a tailwind of higher industrial growth which leads to higher industrial output which in turn leads of higher sale of consumables. Thus, there are quite decent chances that not only the company achieves its revenue target of Rs 400 crores on standalone basis by FY25 but also exceed it. There is also a possibility that the Chandivali land gets sold/developed & gives good profits and/or that is YOUR margin of safety. Maybe the new acquisition done by the company does very well. Maybe Mr. Market continues to give the current multiple & more to the company even in the future. Maybe your margin of safety and return expectations defer from mine.
I have also been overly conservative in such situations in the past and thus it could be that even for this situation my conservatism is (unconsciously) showing up again. Obviously, my views are (and should be!) subject to change based on new data and stock price.
Control PR Q2 FY23 Result Update:
- Installed base of printers: 15500+
- Quarterly Run Rate of Revenue 650mn+ maintained
- Lower availability of semiconductors has impacted sales.
- Higher sales of consumables and share increased in revenue led to better margins during the quarter.
- WC improvement continues to be focus area.
- Gross margins/EBITDA margins maintained above 60% and 23%.
- Low Tax rate due to tax concessions at Guwahati.
- Rising momentum in manufacturing activities as there was higher requirement for consumables.
- Consumables business grew 29% YOY.
- Printer sales were on the lower side due to RM shortages. Trying to mitigate the risks in supply chain.
- Gross margins dropped QOQ was due to RM supplies bought at a higher rate.
- Increase in market share by increase in customer competitive accounts
- Consumables has seen an increased traction in installed base.
- Mark Print BV Netherlands: Acquired 75% stake via a subsidiary
- Dairy & Cement segment are showing growth in business.
- Piping segment still remains the leading industry in this business.
- In Q3, they are expecting good volumes from piping and sugar industry.
- Other income mainly includes dividend income.
- Guwahati Facility Consumables Utilization Level: 50-60%
- Employee cost increased due to salary revisions
- Industries are in the growth phase so consumable sales will increase in H2.
- Expecting some products of Mark Print to be introduced in India by Nov, Dec 2022. Results of the same should be seen in FY23.
- Want to keep INR 50 crores as cash. And the rest will be returned to shareholders.
- Breweries sector eyeing more sales of TIJ Printers.
- Large export order for laser printers in FMCG sector.
- Pipes sector & sugar industry sees increased customer penetration.
Good to see company venturing in Africa.
Another very good set of nos, with 25% sales growth and 48% EPS growth. Concall notes below
- Gross margins were impacted due to supply chain problems in printer parts
- Printer base increases to 16500+ and market share improves to 19% (sold 814 printers in Q3 vs 675 in Q2)
- Printer has a life of 8-12 years, they don’t consider a customer in the printer base if a customer is not operational for 6 months
- Consumables grew by 30% and printers by 20% during Q3
- Scope of improvement in consumable sales, it’s still not operating at optimum utilization
- Sales breakup this quarter: printers (20%), consumables (57%), services (13%), spares (8%)
- Haven’t passed on price increase to customers yet and are going slow on passing on price increases
- Pipe segment is the largest contributor to revenues
- Working aggressively on track and trace technology for pharma sector
- Markprint quarterly revenues: 0.5mn Euro (PAT was ~11% of revenues). Technology transfer has been delayed and will start in March 2023
- Have 350 engineers in sales and services, enough to cover current markets. Might need some specialized services people for custom client projects and a few for sales team
- Sales target for FY25 is 400 cr. (for standalone business)
- ICIPL has suffered more from supply chain issues as its positioning is for more economy cos. They have been unable to supply to lower end customers as ICIPL procures from Control Print and Control Print prioritized higher end customers. Might need to infuse some capital in ICIPL
- 5 more years of tax advantage for Guwahati
- In last 2-3 years, have added a new engine of growth (packaging sector) where earlier they were stronger in industrial segment
- 10 cr. investment in V-shapes SRL JV: high risk opportunity, they bring in new technology and if it works out, it will be a monopoly or at max an oligopoly. End market is pharmaceutical and expensive cosmetics
Disclosure: Invested (position size here, no transactions in last-30 days)
Hi @harsh.beria93 I am new to this company. I have question.
If the total industry size is 1200cr for organised players and there are four players. For the sake of simplicity let’s divide the market size evenly between the four players each one will have a market of 400cr.
That’s a very small market size IMHO and company will find it very very difficult to grow in future at present TTM sales growth of 22%.
What’s your take on expected future revenue growth of company?
Thank you for your time in advance.
Coding and marking is a niche industry and Control Print has a strong positioning within it. Management has mentioned that the industry grows at 1.5x GDP growth. I have collected market sizes over years from different reports.
Indian market size:
- 900 – 1000 cr. (FY16)
- 1200 – 1300 cr. (FY19)
- 1300 – 1500 cr. (FY22)
Growth comes around 6-8% from FY16-22. However, I dont think this is correct as Control Print has grown sales at 11% over this period, despite maintaining similar market share. Please look at market share numbers for Control Print over years.
Indian Market share
- FY15: Domino (32%), Videojet (30.1%), Markem-Imaje (19.9%), Control Print (18.1%)
- FY21: Control Print (18.5%)
- FY22: Control Print (18.5%)
- FY23Q3: Control Print (19%)
FMCG companies like HUL and Nestle have grown their sales at 7-8% over this period (FY16-22). The basic logic behind higher growth in marking and coding industry is that there are more things printed on packaging products over time and that should mean that ink sales growth should be higher than FMCG sales growth. We also see this in Control Print’s growth, where they have grown at 11-12% vs FMCG cos growing at 7-8%. It also kinds of add up with management’s claim of 1.5x GDP growth.
Now coming to the recent spurt in growth, we can see that there has been a recent spurt in printer sales.
Number of installed printers: 5’000 (FY15), 7’000+ (FY18), 13’000 (FY21), 15’000 (FY22), 16’500 (FY23Q3)
Since FY18, installed printer base has more than doubled with sharp growth happening in FY21-23 period. This was because Control Print launched TIJ/TTO printers which are used in the packaging industry, where Control Print had lesser presence. Management has also been mentioning that they are not only winning new business, but also winning competitor’s accounts. Also, they have become much more aggressive in pursuing growth opportunities (launch of lower priced printers for economy segment through ICIPL, going into software solutions for pharma industry through track & trace technology, more export focus, Markprint acquistion, JV with V-shapes SRL, etc.). All this suggests to me that management has become more growth hungry. The good thing with this business is its asset light nature meaning a large part of profitability comes as dividends. Recent spurt in growth is an extra bonus.
Disclosure: Invested (same as before)